Unveiling a New Level of Precision: Discover The Enhanced Prolaris Test Now
Navigate crucial prostate cancer treatment decisions – with the right answers at the right time.
ResourcesAre you a patient?
Myriad needs the contact information you provide to us to contact you about our products and services. You may
unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your
Myriad’s UroSuite™ delivers clinically actionable information for every stage of your patients’ prostate cancer journey.
Gaining individualized genetic insights about your patient’s prostate cancer gives you the information you need to decide on the best treatment plan – and increase their odds for a healthy future.
Testing can significantly alter recommended treatment for improved patient outcomes. Watch this video to learn more.
From industry-leading risk stratification to unmatched variant classification programs, Myriad’s tests lead the industry in clinical utility, helping you clarify risk, make informed decisions and improve outcomes.
Streamlined ordering processes for one or more Myriad Urology tests make it easy to implement efficient workflow solutions into your practice and offer guideline-based care with ease.
Myriad’s Certified Genetic Counselors are available to provide educational support to your patients and answer questions at no cost – before, during and after testing.
Myriad’s UroSuite gives health care providers the ability to directly order a complete suite of tests for comprehensive insights to guide prostate cancer treatment, including:
Myriad Genetics is the only lab to offer comprehensive testing across the spectrum of prostate cancer care, along with best-in-class support and specialists for you and your patients at every step.
Ordering all tests through one company saves time and allows for a more efficient, streamlined process. Our physician portal allows you to easily order multiple tests concurrently and receive results with a simple summary sheet.
“The process that we have is very simple and straightforward. We’re doing the right things for our patients, and not overburdening our staff has become an extremely important part of our practice. We’ve been able to achieve that by working very closely with Myriad.”
Dr. Angelo BaccalaDirector of Urology at Leigh Valley Health Network
Prolaris is the only biomarker with two validated thresholds that provide better risk stratification at biopsy. And Myriad’s germline tests have robust industry-leading variant classification programs and a rigorous verification system. This means that sending all tests – both tumor and germline – to Myriad solves lab discordance and qualifies more patients for targeted therapies and clinical trials.
MyRisk is a germline test that offers a multi-gene panel to determine a patient’s risk of developing secondary cancers, as well as their children’s risk for the same germline mutations. MyRisk can also qualify patients for newer, personalized treatments such as PARP and immunotherapy.
Hereditary cancer test capable of identifying secondary cancer risk to inform treatment decisions and help notify family members who may have inherited the same genetic mutation.
A somatic test that assesses 500+ genes, as well as key biomarkers like MSI, TMB and PD-L1, to determine if a patient’s tumor may be appropriate for novel therapies or clinical trials.
Discover and target important variants only found within the tumors and qualify for new therapies and the most relevant clinical trials.
A cell-cycle proliferation-based biomarker that provides results as early as your patient’s first cancer consultation and determines how aggressive the cancer is behaving. Prolaris eliminates guesswork around cancer risk by combining clinical and pathological features with a personalized tumor aggressiveness score.
A genetic test for untreated men with prostate cancer that can determine how aggressive the cancer may be, how quickly it is growing and which treatment is right for you.
Prolaris® is a molecular diagnostic test that helps determine the aggressiveness of a prostate cancer tumor to guide the best treatment decisions for prostate cancer patients.
Myriad has invested over 30 years in developing tests and solutions that help provide the best answers and care possible.
Our tests are:
Myriad is committed to providing patients with access to accurate and affordable genetic results. Through excellent insurance coverage and financial assistance programs, providers and patients can feel confident knowing Myriad has options for each patient’s situation.
Myriad tests offer industry-leading accuracy so you can feel confident in the results. From hereditary cancer to precision medicine, our tests are designed to give providers and patients the most accurate answers possible.
Myriad makes genetic testing simple with clear, actionable results. We create easy-to-understand reports to ensure that both patients and their providers can use the information to guide treatment options based on national medical guidelines.
Myriad believes that results and genetic information belong to the patient. We take multiple steps to ensure that the security and privacy of patient data is not compromised, and we believe that patients should be in control of their information.
In a recent Myriad Live webinar, our Chief Medical Officer, Thomas Slavin, hosted a lively conversation about prostate cancer with two experts from the field: ...
Last month, Myriad attended the 2023 ASCO Genitourinary Cancers Symposium (ASCO GU) to connect with researchers and doctors around emergent and controversial a...
This casual, yet educational, podcast is committed to keeping you informed on all things urology.
Stay current with clinical validation and utility publications and more.
Find the Myriad documents and forms you need right here.
Read about the latest urology insights and advances.